Angitia Biopharmaceuticals Announces Dosing of First Participant in Phase 2 IDUN Trial of AGA2115 for the Treatment of Osteogenesis Imperfecta
– Phase 2 trial of adults with Osteogenesis Imperfecta (OI) is enrolling patients in the US and EU WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the dosing of the first patient in […]